|
|
Generic
Name |
Ergotamine |
|
Trade Name |
Ergomar |
|
Manufacturer |
|
|
Risk
Category |
|
| X |
- Positive evidence of human fetal risk exists.
- Potential benefits may warrant use of the drug in pregnant women despite potential risks (e.g. life threatening situations or serious illness).
- Studies in animals and/or humans have demonstrated fetal abnormalities.
- Fetal risk involved in use of drug, clearly outweighs potential benefit.
- Contraindicated in women who are or may become pregnant. Don’t use.
|
Place (not
click) your mouse cursor over the bold words in the text
below to receive description
|
Indication |
|
|
 |
- Sympatholytic.
- Ergot alkaloid for treatment of migraine.
|
|
Fetal Risk
|
|
|
 |
- Not teratogenic in animals but fetotoxic at maternal toxic dose causing growth retardation, fetal death and abortion.
- Crosses human placenta, has oxytocic effect on the uterus causing tetanic contractions leading to fetal hypoxia and death.
- Possible association between 1st trimester exposure and congenital defects including neural tube-neural crest dysplasia (hydrocephalus, sacral agenesis, digital and muscle hypoplasia, joint contractures, short stature and pilonidal sinus).
- High doses or chronic use of the drug is associated with fetal vascular injuries related to vasospasm induced by the drug resulting in intestinal atresia, arrest of cerebral and spinal cord development (microcephaly, hypotonia of limbs, paraplegia and arthrogryposis multiplex).
|
|
Breast Feeding
|
|
|
 |
- Excreted into milk.
- Contraindicated in breast-feeding, as it causes vomiting, diarrhea and convulsions in nursing infants.
- It may suppress lactation.
|
|
|
|
